FBIOP
| Market cap | $108.97M |
|---|---|
| Enterprise value | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| Income | -$91.19 |
| Revenue Q/Q | 5.85% |
| Revenue Y/Y | 56.06% |
| P/E | 0.00 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 1.30 |
| P/FCF | N/A |
| Price/Book | 0.41 |
| Book/Share | 18.12 |
| Cash/Share | N/A |
| FCF yield | -143.53% |
| Volume | 205.265k / N/A |
|---|---|
| Relative vol. | N/A |
| EPS | N/A |
|---|---|
| EPS Q/Q | N/A |
| Est. EPS Q/Q | N/A |
| Profit margin | N/A |
|---|---|
| Oper. margin | -263.39% |
| Gross margin | N/A |
| EBIT margin | -237.65% |
| EBITDA margin | N/A |
| Ret. on assets | -34.94% |
|---|---|
| Ret. on equity | -143.38% |
| ROIC | -67.05% |
| ROCE | -75.39% |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.43 |
| Quick ratio | 2.23 |
| Volatility | 13.93% |
|---|---|
| Beta | 1.18 |
| RSI | 11.00 |
|---|
| Insider ownership | 0.00% |
|---|---|
| Inst. ownership | 6.55% |
| Shares outst. | 3.427M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | N/A |
| Short ratio | 0.00 |
| Dividend | $2.34 |
|---|---|
| Dividend yield | 14.38% |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Saturday, 17 February 2024
|
|
| Insider Stock Buying Reaches US$3.06m On Fortress Biotech | |
Wednesday, 5 July 2023
|
|
| Fortress Biotech, Inc.'s Shift From Loss To Profit | |
Thursday, 6 October 2022
|
|
| Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions | |
Thursday, 12 May 2022
|
|
| Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights - Yahoo Finance | |
Thursday, 7 April 2022
|
|
| Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference - Yahoo Finance | |
Monday, 4 April 2022
|
|
| Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities - Yahoo Finance | |
Wednesday, 30 March 2022
|
|
| Shareholders in Fortress Biotech are in the red if they invested a year ago | |
Monday, 28 March 2022
|
|
| Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights - Yahoo Finance | |
Wednesday, 13 October 2021
|
|
| Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition - Yahoo Finance | |
Monday, 13 September 2021
|
|
| What Kind Of Investors Own Most Of Fortress Biotech, Inc. ? | |
Monday, 28 June 2021
|
|
| Hedge Funds Are Selling Fortress Biotech Inc | |
Tuesday, 20 April 2021
|
|
| NOTICE For Investors In NASDAQ: FBIO Shareholder Notice: Lawsuit against Fortress Biotech, Inc announced by Shareholders Foundation | |
Tuesday, 13 April 2021
|
|
| Why Fortress Biotech Stock Is Sinking Today | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| George Avgerinos SVP and Biologics Operations | Sale 11 Dec 2018 | $102,191 |
| Robyn Hunter Chief Financial Officer | Sale 23 Nov 2018 | $26,277 |
| George Avgerinos SVP and Biologics Operations | Sale 14 Dec 2017 | $42,600 |
| George Avgerinos SVP and Biologics Operations | Sale 29 Nov 2017 | $159,643 |
| Lindsay A Md Rosenwald President, CEO, and Chairman | Buy 6 Nov 2017 | $1,000,000 |
| Lindsay A Md Rosenwald President, CEO, and Chairman | Buy 1 Dec 2016 | $1,484 |
| George Avgerinos SVP and Biologics Operations | Sale 15 Sep 2016 | $124,726 |
| Lindsay A Md Rosenwald President, CEO, and Chairman | Buy 1 Jun 2016 | $1,471 |
| Lindsay A Md Rosenwald President, CEO, and Chairman | Buy 1 Dec 2015 | $1,412 |
| Lindsay A Md Rosenwald President, CEO, and Chairman | Buy 1 Jun 2015 | $1,413 |
Dividends
| Ex-dividend date | N/A | Frequency | Monthly | Annual dividend | -0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 14.38% | Growth period | N/A |
| Last dividend date | Yield 3 years | 15.80% | Growth 3 years | -0.00% | |
| Last dividend | Yield 5 years | 13.56% | Growth 5 years | -0.00% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Robyn Hunter (58) Chief Financial Officer, Treasurer, and Secretary since 2017 | 58 | 2017 | $1,798,070 |
| Michael Weiss (54) Executive Vice Chairman - Strategic Development and Director since 2014 | 54 | 2014 | $1,090,020 |
| Lindsay Rosenwald (65) Executive Chairman of the Board, President, and Chief Executive Officer since 2013 | 65 | 2013 | $1,090,020 |
| Robyn M. Hunter (59) CFO, Treasurer, and Corp. Sec. | 59 | $583,105 | |
| Dr. Lindsay Allan Rosenwald (66) Exec. Chairman, Pres, and CEO | 66 | $576,654 | |
| Michael S. Weiss Esq. (55) Vice Chairman and Exec. Vice Chairman of Strategic Devel. | 55 | $576,626 | |
| George Avgerinos (67) Senior Vice President - Biologics Operations since 2013 | 67 | 2013 | $386,347 |
| Eric Rowinsky | 2015 | $278,500 | |
| J. Jay Lobell (57) Independent Director since 2006 | 57 | 2006 | $153,500 |
| Dov Klein (68) Independent Director since 2015 | 68 | 2015 | $146,000 |
| Jimmie Harvey (68) Independent Director since 2008 | 68 | 2008 | $133,500 |
| Malcolm Hoenlein (76) Independent Director since 2014 | 76 | 2014 | $78,000 |
| Kevin Lorenz (55) Independent Director since 2019 | 55 | 2019 | $70,950 |
| Jaclyn Jaffe | 2017 | ||
| Dr. Thomas F. Schaible |
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
- Health Care > Biotechnology
- Fortress Biotech Inc, 2 Gansevoort Street, New York 10014, United States
- 781 652 4500
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Monthly | Annual dividend | -0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 14.38% | Growth period | N/A |
| Last dividend date | Yield 3 years | 15.80% | Growth 3 years | -0.00% | |
| Last dividend | Yield 5 years | 13.56% | Growth 5 years | -0.00% |
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 29 Jun 2022 | 30 Mar 2022 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $248.771 | $287.511 | |||
| Short term investments | |||||
| Net receivables | $29.047 | $31.814 | |||
| Inventory | $16.053 | $16.137 | |||
| Total current assets | $298.991 | $341.186 | |||
| Long term investments | |||||
| Property, plant & equipment | $32.137 | $32.995 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | |||||
| Total investments | |||||
| Total assets | $363.955 | $407.93 | |||
| Current liabilities | |||||
| Accounts payable | $53.939 | $44.532 | |||
| Deferred revenue | |||||
| Short long term debt | $7.487 | $7.363 | |||
| Total current liabilities | $104.921 | $103.14 | |||
| Long term debt | $89.419 | $88.772 | |||
| Total noncurrent liabilities | |||||
| Total debt | |||||
| Total liabilities | $216.253 | $214.352 | |||
| Stockholders' equity | |||||
| Retained earnings | -$584.579 | -$563.223 | |||
| Other stockholder equity | |||||
| Total stockholder equity | $77.22 | $97.856 | |||
| (in millions USD) | 2021 | 2020 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $305.744 | $233.351 | ||
| Short term investments | ||||
| Net receivables | $23.79 | $24.672 | ||
| Inventory | $9.862 | $1.404 | ||
| Total current assets | $346.462 | $266.15 | ||
| Long term investments | $17.566 | |||
| Property, plant & equipment | $34.071 | $32.41 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $396.503 | $333.413 | ||
| Current liabilities | ||||
| Accounts payable | $47.429 | $11.412 | ||
| Deferred revenue | ||||
| Short long term debt | $4.51 | $4.522 | ||
| Total current liabilities | $101.042 | $51.76 | ||
| Long term debt | $46.564 | $59.814 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $170.626 | $136.414 | ||
| Stockholders' equity | ||||
| Retained earnings | -$547.463 | -$482.76 | ||
| Other stockholder equity | ||||
| Total stockholder equity | $108.671 | $100.335 | ||
Income statement
| (in millions USD) | 29 Jun 2022 | 30 Mar 2022 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $18.886 | $23.925 | |||
| Cost of revenue | $8.785 | $44.925 | |||
| Gross profit | $10.101 | -$21 | |||
| Operating activities | |||||
| Research & development | $31.979 | $31.979 | |||
| Selling, general & administrative | $29.048 | $26.27 | |||
| Total operating expenses | $69.812 | $71.195 | |||
| Operating income | -$50.926 | -$47.27 | |||
| Income from continuing operations | |||||
| EBIT | -$50.926 | -$47.27 | |||
| Income tax expense | |||||
| Interest expense | -$3.154 | -$2.35 | |||
| Net income | |||||
| Net income | -$21.356 | -$15.76 | |||
| Income (for common shares) | -$21.356 | -$15.76 | |||
| (in millions USD) | 2021 | 2020 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $68.791 | $45.599 | ||
| Cost of revenue | $154.449 | $78.703 | ||
| Gross profit | -$85.658 | -$33.104 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $86.843 | $61.166 | ||
| Total operating expenses | $241.292 | $139.869 | ||
| Operating income | -$172.501 | -$94.27 | ||
| Income from continuing operations | ||||
| EBIT | -$172.501 | -$94.27 | ||
| Income tax expense | $0.473 | $0.136 | ||
| Interest expense | -$15.308 | -$15.326 | ||
| Net income | ||||
| Net income | -$64.703 | -$46.526 | ||
| Income (for common shares) | -$64.703 | -$46.526 | ||
Cash flows
| (in millions USD) | 29 Jun 2022 | 30 Mar 2022 | |||
|---|---|---|---|---|---|
| Net income | -$21.356 | -$15.76 | |||
| Operating activities | |||||
| Depreciation | $2.222 | $2.196 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | |||||
| Total cash flows from operations | -$41.424 | -$46.86 | |||
| Investing activities | |||||
| Capital expenditures | -$0.307 | -$1.337 | |||
| Investments | |||||
| Total cash flows from investing | -$0.307 | -$21.337 | |||
| Financing activities | |||||
| Dividends paid | -$2.008 | -$2.008 | |||
| Sale and purchase of stock | |||||
| Net borrowings | -$2.888 | $42.188 | |||
| Total cash flows from financing | $2.991 | $49.964 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$38.74 | -$18.233 | |||
| (in millions USD) | 2021 | 2020 | ||
|---|---|---|---|---|
| Net income | -$64.703 | -$46.526 | ||
| Operating activities | ||||
| Depreciation | $6.791 | $5.325 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$116.54 | -$83.682 | ||
| Investing activities | ||||
| Capital expenditures | -$4.566 | -$1.926 | ||
| Investments | ||||
| Total cash flows from investing | $40.514 | -$7.164 | ||
| Financing activities | ||||
| Dividends paid | -$8.031 | -$6.515 | ||
| Sale and purchase of stock | ||||
| Net borrowings | -$14.938 | -$30.171 | ||
| Total cash flows from financing | $148.994 | $172.41 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $72.968 | $81.564 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Northern Trust Corp |
+361.51%
|
46,202 | $92,404 |
| 2024 Q1 | Gladstone Institutional Advisory |
Opened
|
11,500 | $23,000 |
| 2024 Q1 | Royal Bank Of Canada |
-99.82%
|
19 | $0 |
| 2023 Q4 | B. Riley Wealth Advisors |
Opened
|
85,975 | $258,785 |
| 2023 Q4 | Wealth Management Partners |
Sold out
|
20,000 | $60,200 |
| 2023 Q4 | Simplex Trading |
Sold out
|
1,762 | $5 |
| 2023 Q3 | Perkins Capital Management Inc |
Sold out
|
1,406,513 | $408 |
| 2023 Q3 | Platform Technology Partners |
Opened
|
30,000 | $8,709 |
| 2023 Q3 | Creative Planning |
Sold out
|
15,900 | $4,616 |
| 2023 Q3 | Black Maple Capital Management L.P. |
Opened
|
15,000 | $4,355 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Vanguard Group Inc | 153.44% | 5,258,555 | |
| Perkins Capital Management Inc | 41.04% | 1,406,513 | |
| Acadian Asset Management | 31.38% | 1,075,531 | |
| Millennium Management | 9.26% | 317,239 | |
| Kestra Advisory Services | 4.54% | 155,650 | |
| B. Riley Wealth Advisors | 2.51% | 85,975 | |
| Fmr | 2.45% | 84,015 | |
| Virtu Kcg | 1.48% | 50,831 | |
| Northern Trust Corp | 1.35% | 46,202 | |
| Planning Solutions | 1.34% | 46,000 |
Sign up